
EMA approves Moleculin’s application for Phase IIb/III AML trial
The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, multi-centre Phase IIb/III trial of Annamycin plus cytarabine (Ara-C) for adults with acute myeloid leukaemia (AML). The randomised, …